Literature DB >> 10026434

Potential role of cholecystokinin in the development of acute pancreatitis.

C Beglinger1.   

Abstract

Evidence based on animal studies suggests that cholecystokinin (CCK) is involved in the induction and development of acute experimental pancreatitis. However, the results obtained with CCK or CCKA receptor antagonists in different species (rats, mice) and different models of acute pancreatitis (cerulein pancreatitis, hemorrhagic pancreatitis induced by choline-deficient, ethionine-supplemented diet, arginine-induced pancreatitis, sodium taurocholate-induced pancreatitis) produced variable results. The route of administration, the specificity and potency of compounds and the design of the study are predictive for the outcome. Based on the available information, CCK appears to play a contributory role in the development of acute experimental pancreatitis in mice and rats. No conclusions can be drawn from these results with respect to the human disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10026434     DOI: 10.1159/000051456

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

1.  Alpha-lipoic acid protects against cholecystokinin-induced acute pancreatitis in rats.

Authors:  Sung-Joo Park; Sang-Wan Seo; Ok-Sun Choi; Cheung-Seog Park
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction.

Authors:  T D Barrett; W Yan; J M Freedman; G J Lagaud; J G Breitenbucher; N P Shankley
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 3.  L-arginine-induced experimental pancreatitis.

Authors:  Péter Hegyi; Zoltán Rakonczay; Réka Sári; Csaba Góg; János Lonovics; Tamás Takács; László Czakó
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 4.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.